Cargando…
Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus
OBJECTIVE: To identify patient factors associated with change in hemoglobin A1C (A1C) with adjunct pioglitazone therapy in routine clinical practice. METHODS: This was a retrospective analysis of adult type 2 diabetes mellitus patients in a health maintenance organization setting who were newly-init...
Autores principales: | Tran, Mongthuong T., Delate, Thomas, Bachmann, Shakti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141869/ https://www.ncbi.nlm.nih.gov/pubmed/25157285 |
Ejemplares similares
-
Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
por: Tafuri, Kimberly Sue, et al.
Publicado: (2013) -
Correlation between changes in blood pressure with insulin resistance in type 2 diabetes mellitus with four weeks of pioglitazone therapy
por: Dash, Sandip Kumar
Publicado: (2008) -
Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy
por: Hettihewa, L. M., et al.
Publicado: (2008) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014) -
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
por: Park, Jong Suk, et al.
Publicado: (2011)